Supporting Latigo Biotherapeutics in Non-Opioid Drug Discovery

At Neuroservices-Alliance, we take pride in supporting groundbreaking research in CNS and pain drug discovery. In a recent scientific publication by Latigo Therapeutics, our team provided dorsal root ganglia (DRG) from cyno, dogs, and mice for electrophysiological recordings, enabling the evaluation of LTGO33, a promising non-opioid pain therapeutic targeting voltage-gated sodium channels (NaVs).

With chronic pain affecting over 100 million Americans and current treatments facing challenges such as limited efficacy, dependence risks, and poor tolerability, the development of novel pain therapeutics is more critical than ever. Our contribution to this study reinforces Neuroservices-Alliance as a trusted partner for electrophysiology recordings, helping advance innovative treatments for pain disorders.

Our Contribution to the Study:

• Collected dog DRGs from all spinal levels of a male beagle and recorded them in our San Diego, CA facility
• Collected Cynomolgus female monkey (Cyno) DRGs from all spinal levels and recorded them our San Diego, CA facility
• Collected rat DRGs from all spinal levels and recorded them in our San Diego, CA facility
• Neurons were used for patch-clamp recordings up to three days post-dissociation. All work was performed at our San Diego, CA facility
• Dog and Cyno DRG voltage clamp experiments were conducted entirely at our San Diego, CA facility

Click below to download the scientific publication by Latigo Biotherapeutics

Latigo Biotherapeutics Scientific Paper

Book a meeting with us and discuss how our electrophysiology expertise can help accelerate your drug discovery

Send us an email